Roberta S. Teixeira PhD , Arise G.S. Galil PhD , Ana Paula Cupertino PhD , Francisco Cartujano-Barrera MD , Fernando A.B. Colugnati PhD
{"title":"戒烟电子决策工具 (Pare de Fumar Conosco) 与标准护理的对比:成本效益分析","authors":"Roberta S. Teixeira PhD , Arise G.S. Galil PhD , Ana Paula Cupertino PhD , Francisco Cartujano-Barrera MD , Fernando A.B. Colugnati PhD","doi":"10.1016/j.vhri.2024.01.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p>The study aimed to evaluate the cost-effectiveness of the <em>Pare de Fumar Conosco</em> software compared with the standard of care adopted in Brazil for the treatment of smoking cessation.</p></div><div><h3>Methods</h3><p>In the cohort of smokers with multiple chronic conditions, we developed an decision tree model for the benefit measures of smoking cessation. We adopted the perspectives of the Brazilian Unified Health System and the service provider. Resources and costs were measured by primary and secondary sources and effectiveness by a randomized clinical trial. The incremental cost-effectiveness ratio (ICER) was calculated, followed by deterministic and probabilistic sensitivity analyses and deterministic and probabilistic sensitivity analyses. No willingness to pay threshold was adopted.</p></div><div><h3>Results</h3><p>The software had a lower cost and greater effectiveness than its comparator. The ICER was dominant in all of the benefits examined (−R$2 585 178.29 to −R$325 001.20). The cost of the standard of care followed by that of the electronic tool affected the ICER of the benefit measures. In all probabilistic analyses, the software was superior to the standard of care (53.6%-82.5%).</p></div><div><h3>Conclusion</h3><p>The <em>Pare de Fumar Conosco</em> software is a technology that results in cost savings in treating smoking cessation.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2212109924000074/pdfft?md5=c7fcc99e4e5465c7e9b666a4fedccb81&pid=1-s2.0-S2212109924000074-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Electronic Decision-Making Tool for Smoking Cessation (Pare de Fumar Conosco) Versus Standard of Care: A Cost-Effectiveness Analysis\",\"authors\":\"Roberta S. Teixeira PhD , Arise G.S. Galil PhD , Ana Paula Cupertino PhD , Francisco Cartujano-Barrera MD , Fernando A.B. Colugnati PhD\",\"doi\":\"10.1016/j.vhri.2024.01.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><p>The study aimed to evaluate the cost-effectiveness of the <em>Pare de Fumar Conosco</em> software compared with the standard of care adopted in Brazil for the treatment of smoking cessation.</p></div><div><h3>Methods</h3><p>In the cohort of smokers with multiple chronic conditions, we developed an decision tree model for the benefit measures of smoking cessation. We adopted the perspectives of the Brazilian Unified Health System and the service provider. Resources and costs were measured by primary and secondary sources and effectiveness by a randomized clinical trial. The incremental cost-effectiveness ratio (ICER) was calculated, followed by deterministic and probabilistic sensitivity analyses and deterministic and probabilistic sensitivity analyses. No willingness to pay threshold was adopted.</p></div><div><h3>Results</h3><p>The software had a lower cost and greater effectiveness than its comparator. The ICER was dominant in all of the benefits examined (−R$2 585 178.29 to −R$325 001.20). The cost of the standard of care followed by that of the electronic tool affected the ICER of the benefit measures. In all probabilistic analyses, the software was superior to the standard of care (53.6%-82.5%).</p></div><div><h3>Conclusion</h3><p>The <em>Pare de Fumar Conosco</em> software is a technology that results in cost savings in treating smoking cessation.</p></div>\",\"PeriodicalId\":23497,\"journal\":{\"name\":\"Value in health regional issues\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2024-04-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2212109924000074/pdfft?md5=c7fcc99e4e5465c7e9b666a4fedccb81&pid=1-s2.0-S2212109924000074-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Value in health regional issues\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2212109924000074\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Value in health regional issues","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2212109924000074","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
摘要
研究旨在评估 Pare de Fumar Conosco 软件与巴西采用的标准戒烟治疗方法相比的成本效益。我们采用了巴西统一卫生系统和服务提供者的观点。资源和成本通过第一手和第二手资料进行测算,有效性通过随机临床试验进行测算。我们计算了增量成本效益比(ICER),然后进行了确定性和概率敏感性分析以及确定性和概率敏感性分析。没有采用支付意愿阈值。ICER 在所有研究效益中均占优势(-2 585 178.29 至-325 001.20 美元)。标准护理的成本和电子工具的成本影响了效益指标的 ICER。结论 Pare de Fumar Conosco 软件是一种可节省戒烟治疗成本的技术。
Electronic Decision-Making Tool for Smoking Cessation (Pare de Fumar Conosco) Versus Standard of Care: A Cost-Effectiveness Analysis
Objectives
The study aimed to evaluate the cost-effectiveness of the Pare de Fumar Conosco software compared with the standard of care adopted in Brazil for the treatment of smoking cessation.
Methods
In the cohort of smokers with multiple chronic conditions, we developed an decision tree model for the benefit measures of smoking cessation. We adopted the perspectives of the Brazilian Unified Health System and the service provider. Resources and costs were measured by primary and secondary sources and effectiveness by a randomized clinical trial. The incremental cost-effectiveness ratio (ICER) was calculated, followed by deterministic and probabilistic sensitivity analyses and deterministic and probabilistic sensitivity analyses. No willingness to pay threshold was adopted.
Results
The software had a lower cost and greater effectiveness than its comparator. The ICER was dominant in all of the benefits examined (−R$2 585 178.29 to −R$325 001.20). The cost of the standard of care followed by that of the electronic tool affected the ICER of the benefit measures. In all probabilistic analyses, the software was superior to the standard of care (53.6%-82.5%).
Conclusion
The Pare de Fumar Conosco software is a technology that results in cost savings in treating smoking cessation.